Long‐term risk of second malignant neoplasms after neuroblastoma in childhood: Role of treatment

Open Access
Publisher Website
Google Scholar
Abstract
The aim of our study was to quantify the risk of second malignant neoplasms (SMNs) among long‐term survivors of neuroblastoma and to study the influence of treatment on this risk. We studied data from 544 5‐year survival patients diagnosed with neuroblastoma before age 16 years at 8 French and British treatment centres from 1948 to 1986. After an average follow‐up of 15 years (range, 5–38 years), 12 children developed a total of 13 SMNs, whereas 1.19 were expected from general population rates. Among these SMNs, there were 5 thyroid and 3 breast cancers. Increases of the risks of SMN were observed with time since neuroblastoma diagnosis and attained age. In a multivariate analysis, the relative risk of SMN associated with radiotherapy was 4.3 (95% CI 0.8–78), whereas no increased risk of SMN was associated with the administration of chemotherapy as a whole (RR = 0.4, 95% CI 0.1–1.9). Young children treated for a neuroblastoma have significantly increased risks of SMN over 3 decades of follow‐up. Radiotherapy treatment was found to be an important risk factor for developing SMNs, whereas no effect of chemotherapy was evidenced. Although our findings reflect the late effects of past therapeutic modalities, they underscore the importance of long‐term surveillance of young children treated for a neuroblastoma. For these patients, many more years of follow‐up are required to appreciate their overall risks of treatment‐related SMNs.
Funding Information
  • “Radioprotection” and the “Europe Against Cancer” Programs of the European Communities
  • Institut Gustave Roussy
  • Institut National de la Sante et de la Recherche Medicale (INSERM)
  • Caisse Nationale Assurance Maladie des Travailleurs Sociaux (CNAMTS)
  • Electricité de France (EDF)
  • Snecma
  • Framatome
  • Association pour la Recherche sur le Cancer (ARC)
  • Comities “Champagne Ardennes”
  • “Essonne” and “Val d'Oise” of the Ligue Nationale Contre le Cancer (LNCC)